Roche To Set Right Avastin Post-Marketing Surveillance Delay In India
Roche is working towards implementing PMS studies for Avastin (bevacizumab) and ensuring that a suspension of marketing authorization for the product in first line ovarian cancer is lifted in India.
You may also be interested in...
Are drug firms being lax when it comes to Phase IV studies in markets like India or are certain arbitrarily determined regulatory requirements largely to blame? Scrip delves into the issue.
Yesteryear rivals Roche and Cipla have sewn up a partnership under which Cipla will market a second brand of the Swiss giant’s Avastin (bevacizumab) and the
Biocon has launched its biosimilar Avastin in India, intensifying competition on the market. In addition to its ‘affordable’ price, Biocon’s biosimilar Avastin also comes with a novel temperature-sensitive packaging, which it sees as a key differentiator. Roche meanwhile underscored the need to be “very careful” while making packaging changes with biologics.